Where to Start

Gilman, A. G. 2012. Silver spoons and other personal reflections. Annu. Rev. Pharmacol. Toxicol. 52:1–19.

Zhang, H.-Y., Chen, L.-L., Xue-Juan Li, X.-J. and Zhang, J. 2010. Evolutionary inspirations for drug discovery. Trends Pharmacol. Sci. 31:443–448.

Kenakin, T. P. 2014. A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery (4th ed.). Academic Press.

Brunton, L., Chabner, B., and Knollman, B. 2011. Goodman and Gilman’s The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional.

Walsh, C. T., and Schwartz-Bloom, R. D. 2004. Levine’s Pharmacology: Drug Actions and Reactions (7th ed.). Taylor and Francis Group.

Silverman, R. B., and Holladay, M. W. 2014. Organic Chemistry of Drug Design and Drug Action (3d ed.). Academic Press.

Walsh, C. 2003. Antibiotics: Actions, Origins, Resistance. ASM Press.

Caldwell, J., Gardner, I., and Swales, N. 1995. An introduction to drug disposition: The basic principles of absorption, distribution, metabolism, and excretion. Toxicol. Pathol. 23:102–114.

Lee, W., and Kim, R. B. 2004. Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol. 44:137–166.

Lin, J., Sahakian, D. C., de Morais, S. M., Xu, J. J., Polzer, R. J., and Winter, S. M. 2003. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr. Top. Med. Chem. 3:1125–1154.

Poggesi, I. 2004. Predicting human pharmacokinetics from preclinical data. Curr. Opin. Drug Discov. Devel. 7:100–111.

Flower, R. J. 2003. The development of COX2 inhibitors. Nat. Rev. Drug Discov. 2:179–191.

Tobert, J. A. 2003. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2:517–526.

Vacca, J. P., Dorsey, B. D., Schleif, W. A., Levin, R. B., McDaniel, S. L., Darke, P. L., Zugay, J., Quintero, J. C., Blahy, O. M., Roth, E., et al. 1994. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 91:4096–4100.

Wong, S., and Witte, O. N. 2004. The BCR-ABL story: Bench to bedside and back. Annu. Rev. Immunol. 22:247–306.

Kuntz, I. D. 1992. Structure-based strategies for drug design and discovery. Science 257:1078–1082.

Dorsey, B. D., Levin, R. B., McDaniel, S. L., Vacca, J. P., Guare, J. P., Darke, P. L., Zugay, J. A., Emini, E. A., Schleif, W. A., Quintero, J. C., et al. 1994. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443–3451.

Chen, Z., Li, Y., Chen, E., Hall, D. L., Darke, P. L., Culberson, C., Shafer, J. A., and Kuo, L. C. 1994. Crystal structure at 1.9-Å resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J. Biol. Chem. 269:26344–26348.

Baldwin, J. J. 1996. Design, synthesis and use of binary encoded synthetic chemical libraries. Mol. Divers. 2:81–88.

Burke, M. D., Berger, E. M., and Schreiber, S. L. 2003. Generating diverse skeletons of small molecules combinatorially. Science 302:613–618.

Edwards, P. J., and Morrell, A. I. 2002. Solid-phase compound library synthesis in drug design and development. Curr. Opin. Drug Discov. Devel. 5:594–605.

Zambrowicz, B. P., and Sands, A. T. 2003. Knockouts model the 100 best-selling drugs: Will they model the next 100? Nat. Rev. Drug Discov. 2:38–51.

Salemme, F. R. 2003. Chemical genomics as an emerging paradigm for postgenomic drug discovery. Pharmacogenomics 4:257–267.

Michelson, S., and Joho, K. 2000. Drug discovery, drug development and the emerging world of pharmacogenomics: Prospecting for information in a data-rich landscape. Curr. Opin. Mol. Ther. 2:651–654.

Weinshilboum, R., and Wang, L. 2004. Pharmacogenomics: Bench to bedside. Nat. Rev. Drug Discov. 3:739–748.

B44

B45